<DOC>
	<DOCNO>NCT01204580</DOCNO>
	<brief_summary>Primary Objective : To evaluate change plasma level adiponectin Asymmetric Dimethylarginine ( ADMA ) type 2 diabetes patient 12 week treatment Amaryl-M Secondary Objectives : 1 . To assess role Amaryl-M change plasma level adiponectin ADMA type 2 diabetes patient 8 week therapy 2 . To evaluate brachial-ankle pulse wave velocity ( baPWV ) change 8 12 week therapy Amaryl-M 3 . To evaluate efficacy Amaryl-M improvement patient glycemic level ( Fasting blood glucose ( FBG ) glycosylated hemoglobin ( HbA1c ) ) 4 . To evaluate change Tumor Necrosis Factor - Alfa ( TNF-Alfa ) 12 week therapy Amaryl-M 5 . To evaluate Homeostatic Model Assessment Insulin Resistance ( HOMA-IR ) change 12 week therapy Amaryl-M 6 . To evaluate HOMA-Î² change 12 week therapy Amaryl-M 7 . To evaluate relationship adiponectin ADMA level FBG HbA1c level</brief_summary>
	<brief_title>ADIponectin Asymmetric Dimethylarginine ( ADMA ) Level Type-2 Diabetes Patients After 12 Weeks Treatment With GlimepiRide And Metformin Fixed Dose Combination</brief_title>
	<detailed_description>The clinical trial consist 2 week selection follow 12 week ( 3 month ) treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>N , N-dimethylarginine</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus patient Patients HbA1c &gt; or= 7.0 % &lt; 10.0 % Patients currently treat oral antidiabetic drug ( OADs ) Exclusion criterion : Participation investigational Clinical Trial Current temporary insulin treatment : gestational diabetes , pancreas cancer , surgery etc . Women pregnant lactate Type 1 diabetes mellitus patient Treatment antihypertensive AngiotensinConverting Enzyme ( ACE ) Inhibitors and/or Angiotensin II Receptor Blocker ( ARB ) stop treatment le two month Treatment lipid lower agent statin stop treatment le two month Known hypersensitive excipients AmarylM , sulphonylureas , sulfonamide biguanide Patients active smoke history smoke cessation le 2 month Patients history severe hepatic dysfunction Patients serum creatinine &gt; or= 1.5 mg/dL ( male ) &gt; or= 1.4 mg/dL ( female ) Patients congestive heart failure require pharmacologic treatment Treatment antifungal agent especially Miconazole The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>